Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4622220 | 1.00 | BACE1 (0.52) | BACE1CTSD | |
| SCHEMBL4620827 | 0.89 | BACE1 (0.45) | BACE1CTSD | |
| SCHEMBL4621121 | 0.89 | BACE1 (0.45) | BACE1CTSD | |
| SCHEMBL4623040 | 0.88 | BACE1 (0.44) | BACE1CTSD | |
| SCHEMBL3187708 | 0.84 | CTSD (0.58) | BACE1CTSD | |
| SCHEMBL4336000 | 0.82 | CTSD (0.55) | BACE1CTSD | |
| SCHEMBL3261066 | 0.81 | CTSD (0.69) | BACE1CTSD | |
| SCHEMBL3259588 | 0.81 | CTSD (0.69) | BACE1CTSD | |
| SCHEMBL3260979 | 0.81 | CTSD (0.69) | BACE1CTSD | |
| SCHEMBL3263985 | 0.81 | CTSD (0.69) | BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070885-A1 | MACROCYCLIC COMPOUNDS HAVING ASPARTIC PROTEASE INHIBITING ACTIVITY AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2008-03-20 | — | — | US | disclosed |
| EP-1654241-B1 | MACROCYCLIC COMPOUNDS HAVING ASPARTIC PROTEASE INHIBITING ACTIVITY AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2008-03-19 | — | — | EP | disclosed |
| US-20060223745-A1 | Macrocyclic compounds having aspartic protease inhibiting activity and pharmaceutical uses thereof | BETSCHART CLAUDIA | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223745-A1 | Macrocyclic compounds having aspartic protease inhibiting activity and pharmaceutical uses thereof | BACE1, APP, ACE | BACE1 1/4885CTSD 103/4885 |
| US-20080070885-A1 | MACROCYCLIC COMPOUNDS HAVING ASPARTIC PROTEASE INHIBITING ACTIVITY AND PHARMACEUTICAL USES THEREOF | BACE1, APP, BACE2 | BACE1 1/4885CTSD 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.